Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06106698

Washed Microbiota Transplantation for Clostridioides Difficile Infection

Clostridioides Difficile Infection Clinical Trial

Official title:
Washed Microbiota Transplantation for Clostridioides Difficile Infection: a Real World Research

Clinical Trial Summary

This is a real-world study to explore the safety and the efficacy of washed microbiota transplantation （WMT） for patients with Clostridioides Difficile Infection （CDI）.

Clinical Trial Description

At least 12 subjects who meet all the inclusion criteria but do not meet any exclusion criteria will be enrolled in this study. Data of demographic characteristics, intestinal symptoms, medicine treatment usage and clinical outcomes will be collected. After treatment, they will enter the follow-up period （at least for 4-week post-WMT）for safety and efficacy evaluation. Subjects with no response and recurrence will receive salvage therapy, and the extended follow-up period will be performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06106698
Study type Observational
Source The Second Hospital of Nanjing Medical University
Contact Faming Zhang, PhD
Phone 086-025-58509883
Email fzhang@njmu.edu.cn
Status Recruiting
Phase
Start date July 22, 2023
Completion date December 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Completed NCT04675723 - The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
Withdrawn NCT04679324 - The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
Recruiting NCT05693077 - Clostridioides Difficile Colonisation Phase 1
Completed NCT04668014 - The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
Completed NCT03183141 - ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05709184 - Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection N/A
Terminated NCT05526807 - Ursodeoxycholic Acid in C. Difficile Infection N/A
Recruiting NCT06306014 - Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients Phase 1/Phase 2
Recruiting NCT06237452 - VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 3
Terminated NCT04802837 - Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects Phase 3
Active, not recruiting NCT04885946 - Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection N/A
Recruiting NCT04305769 - Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Phase 2
Active, not recruiting NCT04781387 - Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection Phase 2
Completed NCT03595553 - Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT03595566 - To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT04725123 - Addressing Personalized Needs in Clostridioides Difficile Infection N/A
Not yet recruiting NCT05852587 - Xylitol Use for Decolonization of C. Difficile in Patients With IBD Phase 1
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Recruiting NCT05612672 - Evaluation of GeoHAI Implementation N/A